UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 440

Sortiert nach

Leveraging genetic diversity to identify small molecules that reverse mouse skeletal muscle insulin resistance

eLife, 2023-07, Vol.12

2023

Link zum Volltext

Verfügbarkeit prüfen

The genetic and dietary landscape of the muscle insulin signalling network

eLife, 2024-02, Vol.12

2024

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

American journal of ophthalmology, 2001-05, Vol.131 (5), p.631-635

2001

Link zum Volltext

Verfügbarkeit prüfen

Dual Tracer Test to Measure Tissue-Specific Insulin Action in Individual Mice Identifies In Vivo Insulin Resistance Without Fasting Hyperinsulinemia

Diabetes (New York, N.Y.), 2024-03, Vol.73 (3), p.359

2024

Link zum Volltext

Verfügbarkeit prüfen

1773-P: Beta-Catenin Is a Key Player in Insulin-Stimulated Skeletal Muscle Glucose Transport

Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

2019

Link zum Volltext

Verfügbarkeit prüfen

The genetic and dietary landscape of the muscle insulin signalling network

eLife, 2024-02, Vol.12

2024

Link zum Volltext

Verfügbarkeit prüfen

Leveraging genetic diversity to identify small molecules that reverse mouse skeletal muscle insulin resistance

eLife, 2023-07, Vol.12

2023

Link zum Volltext

Verfügbarkeit prüfen

Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure

American journal of ophthalmology, 2000-06, Vol.129 (6), p.723-727

2000

Link zum Volltext

Verfügbarkeit prüfen

24-Hour Intraocular Pressure Control with Maximum Medical Therapy Compared with Surgery in Patients with Advanced Open-Angle Glaucoma

Ophthalmology (Rochester, Minn.), 2006-05, Vol.113 (5), p.761-765.e1

2006

Link zum Volltext

Verfügbarkeit prüfen

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients

Ophthalmology (Rochester, Minn.), 2005-02, Vol.112 (2), p.262-266

2005

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Bimatoprost in Patients with Elevated Intraocular Pressure: A 30-Day Comparison with Latanoprost

Survey of ophthalmology, 2001-05, Vol.45, p.S353-S360

2001

Link zum Volltext

Verfügbarkeit prüfen

Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

American journal of ophthalmology, 2003-03, Vol.135 (3), p.314-320

2003

Link zum Volltext

Verfügbarkeit prüfen

24-Hour Intraocular Pressures with Brimonidine Purite versus Dorzolamide Added to Latanoprost in Primary Open-Angle Glaucoma Subjects

Ophthalmology (Rochester, Minn.), 2005-04, Vol.112 (4), p.603-608

2005

Link zum Volltext

Verfügbarkeit prüfen

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

Eye (London), 2006-05, Vol.20 (5), p.583-590

2006

Link zum Volltext

Verfügbarkeit prüfen

STAT 5 activators can replace the requirement of FBS in the adipogenesis of 3T3-L1 cells

Biochemical and biophysical research communications, 2004-11, Vol.324 (1), p.355-359

2004

Link zum Volltext

Verfügbarkeit prüfen

The Regulation and Activation of Ciliary Neurotrophic Factor Signaling Proteins in Adipocytes

The Journal of biological chemistry, 2003-01, Vol.278 (4), p.2228-2235

2003

Link zum Volltext

Verfügbarkeit prüfen

Twenty-four–hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination

Ophthalmology (Rochester, Minn.), 2003-07, Vol.110 (7), p.1357-1360

2003

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with long-term progression or stability in primary open-angle glaucoma

American journal of ophthalmology, 2000-09, Vol.130 (3), p.274-279

2000

Link zum Volltext

Verfügbarkeit prüfen

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six-month, masked, multicenter trial in the United States

Ophthalmology (Rochester, Minn.), 1996, Vol.103 (1), p.138-147

CAMRAS, C. B

1996

Link zum Volltext

Verfügbarkeit prüfen

Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment

Journal of ocular pharmacology and therapeutics, 2004-12, Vol.20 (6), p.461-469

2004

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

American journal of ophthalmology, 1999-07, Vol.128 (1), p.15-20

1999

Link zum Volltext

Verfügbarkeit prüfen

A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol

American journal of ophthalmology, 2002-06, Vol.133 (6), p.753-757

2002

Link zum Volltext

Verfügbarkeit prüfen

Washout periods for brimonidine 0.2% and latanoprost 0.005

American journal of ophthalmology, 2001-06, Vol.131 (6), p.798-799

2001

Link zum Volltext

Verfügbarkeit prüfen

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005% timolol maleate 0.5% and dorzolamide 2% timolol maleate 0.5

Eye (London), 2004-12, Vol.18 (12), p.1264-1269

2004

Link zum Volltext

Verfügbarkeit prüfen

Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

Eye (London), 2004-09, Vol.18 (9), p.905-910

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(360)
Mit Volltextzugriff
(326)

Publikationsform

Sprache

Englisch
(440)
Japanisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(411)
Life Sciences & Biomedicine
(366)
Humans
(270)
Female
(187)
Biological And Medical Sciences
(171)
Male
(162)
Medical Sciences
(156)
Ophthalmology
(150)
Middle Aged
(97)
Aged
(87)
Animals
(87)
Adult
(71)
Pharmacology. Drug Treatments
(60)
Glaucoma, Open-Angle - Drug Therapy
(53)
Intraocular Pressure - Drug Effects
(50)
Prospective Studies
(46)
Physical Sciences
(43)
Intraocular Pressure
(42)
Glaucoma
(40)
Eye
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Leveraging genetic diversity to identify small molecules that reverse mouse skeletal muscle insulin resistance

The genetic and dietary landscape of the muscle insulin signalling network

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

Dual Tracer Test to Measure Tissue-Specific Insulin Action in Individual Mice Identifies In Vivo Insulin Resistance Without Fasting Hyperinsulinemia

1773-P: Beta-Catenin Is a Key Player in Insulin-Stimulated Skeletal Muscle Glucose Transport

The genetic and dietary landscape of the muscle insulin signalling network

Leveraging genetic diversity to identify small molecules that reverse mouse skeletal muscle insulin resistance

Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure

24-Hour Intraocular Pressure Control with Maximum Medical Therapy Compared with Surgery in Patients with Advanced Open-Angle Glaucoma

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients

Efficacy and Safety of Bimatoprost in Patients with Elevated Intraocular Pressure: A 30-Day Comparison with Latanoprost

Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

24-Hour Intraocular Pressures with Brimonidine Purite versus Dorzolamide Added to Latanoprost in Primary Open-Angle Glaucoma Subjects

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

STAT 5 activators can replace the requirement of FBS in the adipogenesis of 3T3-L1 cells

The Regulation and Activation of Ciliary Neurotrophic Factor Signaling Proteins in Adipocytes

Twenty-four–hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination

Factors associated with long-term progression or stability in primary open-angle glaucoma

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma : a six-month, masked, multicenter trial in the United States

Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol

Washout periods for brimonidine 0.2% and latanoprost 0.005

Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005% timolol maleate 0.5% and dorzolamide 2% timolol maleate 0.5

Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects

Suchergebnisse filtern